Ajanta Pharma Limited has announced an in-licensing agreement with Biocon Limited for the marketing of Semaglutide, a GLP-1 receptor agonist. Under this agreement, Biocon will supply Semaglutide to Ajanta for exclusive marketing in 23 countries and semi-exclusive marketing in 3 countries across Africa, the Middle East, and Central Asia. Semaglutide is used to improve glycaemic control in adults. The product patent is set to expire in most of these markets in March 2026. Ajanta Pharma plans to launch the product commercially after obtaining regulatory approvals, which are anticipated in late 2026 or early 2027. Ajanta Pharma has a strong established branded generic business in over 30 countries across Africa, South-East Asia, Central Asia, and the Middle East, with a presence in various therapeutic segments. Yogesh Agrawal, Managing Director of Ajanta Pharma Ltd., expressed excitement about partnering with Biocon, stating that GLP-1 therapies have seen rapid global acceptance and become blockbuster products. He is confident in building Semaglutide into a meaningful and high-growth brand in these regions. Siddharth Mittal, CEO and MD of Biocon Ltd., highlighted that this partnership is a strategic step to expand the global footprint of Biocon’s GLP-1 portfolio and maximize value from their scientific investments. He also mentioned that the collaboration will enable broader and more affordable access to Semaglutide for patients in these regions. For the fiscal year 2024-25, Ajanta Pharma reported a Revenue of ₹4,648 crore, EBIDTA of ₹1,260 crore (27%), and PAT of ₹920 crore (20%). The company has achieved a healthy revenue CAGR of 11% and a PAT CAGR of 25% over the last three financial years.
